The FDA has approved Kerendia® (finerenone) to reduce the risk of cardiovascular death, hospitalization for HF, and urgent HF visits.

Patients with heart failure and atrial fibrillation (AF) at the time of mitral transcatheter edge-to-edge repair (M-TEER) for ...

BACKGROUND: Neurodevelopmental and functional impairments are among the most consequential morbidities for survivors of ...

The study revealed that people with these genetic changes were found to be more than twice as likely to develop heart failure ...

Researchers at the German Center for Cardiovascular Research (DZHK) have identified a key molecule involved in a form of ...

Patients with heart failure and atrial fibrillation (AF) at the time of mitral transcatheter edge-to-edge repair (M-TEER) for ...

Bayer announced the FDA approved finerenone, a nonsteroidal selective mineralocorticoid receptor antagonist, for the ...

Background Although treatment options for heart failure (HF) have improved, advanced HF (AdHF) remains a challenging ...